

Valproate audit data collection table

Patient initials:									Sheet Total		
Patient who is of childbearing potential has been dispensed a prescription for valproate:		Pt Y/N	Pt Y/N	Pt Y/N	Pt Y/N	Pt Y/N	Pt Y/N	Pt Y/N	Total Y	Total N	Total DK
1.	Has the patient agreed to discuss their valproate medicine with the pharmacist? (<i>Patients representative, if appropriate</i>)										
2.	Has the patient been provided with advice and information in line with the MHRA Drug Safety Update 2018, including the potential impact on an unborn child? See MHRA Drug Safety Update for full requirements and summary of actions for pharmacists below*										
3.	Has the patient representative been provided with advice and information in line with the MHRA Drug Safety Update 2018, including the potential impact on an unborn child? * (only if appropriate)										
4.	Does the patient (or patient representative, where appropriate) have a copy of the Patient Guide and if not, have they been provided with a copy of this?										
5.	Has the patient (or patient representative, where appropriate) been provided with a Patient Card? (A Patient Card should be provided every time valproate is dispensed)										
6.	Has the patient seen their GP or specialist to discuss their use of valproate and the need for appropriate contraception in the past 12 months? (<i>If patient representative does not know the answer please record as 'DK'</i>)										
7.	Does the patient have highly effective contraception in line with the pregnancy prevention programme?										
8.	Was the patient referred/signposted back to their GP or specialist to discuss contraception? (<i>only if appropriate</i>)										
9.	Is the detail of the above intervention, the provision of Patient Guide (if required) and Patient Card recorded on the PMR, or appropriate patient record?										

*Actions for pharmacists • Ensure the Patient Card is provided every time valproate is dispensed • Remind patients of the risks in pregnancy and the need for highly effective contraception • Remind patients of the need for annual specialist review • Ensure the patient has received the Patient Guide • Dispense valproate in the original package. In situations where repackaging cannot be avoided always provide a copy of the package leaflet and add a label with the warning to the outer box • If a woman of childbearing potential reports that she is not taking highly effective contraception, refer them to their GP (including by contacting the GP if necessary).